Jefferies resumed coverage on Vaxart with a new price target
$VXRT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Jefferies resumed coverage of Vaxart with a rating of Buy and set a new price target of $12.00 from $13.00 previously